Elexacaftor/Ivacaftor/Tezacaftor: First Approval

This article summarizes the milestones in the development of elexacaftor/ivacaftor/tezacaftor leading to this first approval for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1F508del mutation in theCFTR gene.

http://link.springer.com/10.1007/s40265-019-01233-7

Source: Drugs - November 28, 2019 Category: Drugs & Pharmacology Source Type: research